Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 6/20 | 0.62 |
| ▸ | THRA | P10827 | 5/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 3/20 | 0.59 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28657555 | 0.98 | TP53 (0.67) | TP53TSHRTHRBTHRAPLA2G4B | |
| SCHEMBL27424165 | 0.97 | THRB (0.63) | TP53TSHRTHRBTHRAPLA2G4B | |
| SCHEMBL14192502 | 0.92 | L3MBTL1 (0.58) | TP53TSHRTHRBTHRAPLA2G4B | |
| SCHEMBL4577939 | 0.90 | NPC1 (0.66) | TP53TSHRTHRBTHRAPLA2G4B | |
| SCHEMBL14192484 | 0.90 | GAA (0.59) | TP53TSHRTHRBTHRAPLA2G4B | |
| SCHEMBL14192473 | 0.88 | THRB (0.72) | TP53TSHRTHRBTHRAMEN1 | |
| SCHEMBL14192425 | 0.87 | NPC1 (0.62) | TP53TSHRTHRBTHRAPLA2G4B | |
| SCHEMBL14192458 | 0.87 | THRB (0.73) | TP53TSHRTHRBTHRAMEN1 | |
| SCHEMBL14192568 | 0.85 | THRA (0.48) | TP53TSHRTHRBTHRAPLA2G4B | |
| SCHEMBL14192478 | 0.84 | THRB (0.68) | TP53TSHRTHRBTHRAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | TP53 3997/4885TSHR 2112/4885THRB 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.